全球中枢性性早熟 (CPP) 治疗市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球中枢性性早熟 (CPP) 治疗市场 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Central Precocious Puberty Cpp Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 1,482.52 Million
Diagram Market Size (Forecast Year)
USD 2,663.78 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>全球中枢性性早熟 (CPP)治疗市场,按类型(药物、手术)、诊断(血液检查、MRI、CT 扫描、X 射线)、月份(1 个月、2 个月、6 个月、其他)、给药途径(肠外、植入、口服、其他)、性别(女孩、男孩)、最终用户(医院、专科诊所、家庭护理、其他)、分销渠道(医院药房、零售药房、网上药房、其他)– 行业趋势和预测到 2029 年。

中枢性性早熟(CPP)治疗市场

市场分析和规模

近年来,中枢性性早熟 (CPP) 治疗市场预计在预测期内将快速增长。促性腺激素释放激素 (GnRH) 激动剂可用于治疗 CPP,因为它们可阻断内源性 GnRH 的刺激作用并加速骨骼发育,从而防止性早熟。使用 GnRH 治疗来延迟青春期开始时,月经初潮会延迟。Triptodor、Lupron Depot-Ped(醋酸亮丙瑞林)和 Supprelin LA(醋酸组氨瑞林)是目前市场上三种获批的中枢性性早熟 (CPP) 治疗药物。

Data Bridge Market Research 分析称,2021 年中枢性性早熟 (CPP) 治疗市场价值为 14.8252 亿美元,预计到 2029 年将达到 26.6378 亿美元,在 2022 年至 2029 年的预测期内复合年增长率为 7.60%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

促性腺激素依赖性性早熟被称为中枢性性早熟 (CPP)。这是一种内分泌相关的发育障碍,其特点是青春期变化、第二性征、更快的生长和骨骼成熟发生在典型青春期年龄之前(女孩 8 岁,男孩 9 岁)。这是一种特发性疾病。然而,MKRN3 基因突变是中枢性性早熟最常见的已知遗传原因。

报告范围和市场细分

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

类型(药物、手术)、诊断(血液检查、MRI、CT 扫描、X 光)、月份(1 个月、2 个月、6 个月、其他)、给药途径(肠外、植入、口服、其他)、性别(女孩、男孩)、最终用户(医院、专科诊所、家庭护理、其他)、分销渠道(医院药房、零售药房、网上药房、其他)

覆盖国家

北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区

涵盖的市场参与者

赛诺菲(法国)、辉瑞公司(美国)、葛兰素史克公司(英国)、诺华公司(瑞士)、艾伯维公司(美国)、罗氏公司(瑞士)、迈兰公司(美国)、梯瓦制药工业有限公司(爱尔兰)、益普生制药(法国)、Arbor Pharmaceuticals(美国)、Tolmar Pharmaceuticals, Inc.(美国)、GP Pharm(西班牙)、Debiopharm(瑞士)、大熊制药株式会社(韩国)、太阳制药工业有限公司(印度)、武田制药株式会社(日本)、Endo International plc(爱尔兰)、阿斯利康(英国)、强生私人有限公司(美国)

市场机会

  • 新兴市场数量增加
  • 增加研发活动数量
  • 加大对先进技术开发的投资
  • 药品审批和上市数量激增

中枢性性早熟 (CPP) 治疗市场动态

驱动程序

  • 激素紊乱患病率不断上升

预计荷尔蒙失调患病率的上升将影响市场增长率。与此同时,肥胖发病率的上升也将影响预测期内的市场动态。  

  • 增加医疗基础设施投资

影响中枢性性早熟 (CPP) 治疗市场增长率的另一个重要因素是医疗保健支出的增加,这有助于改善其基础设施。

此外,公共和私人组织不断增加的宣传活动将扩大中枢性性早熟 (CPP) 治疗市场。此外,高可支配收入和对疾病特异性治疗的需求增加将导致中枢性性早熟 (CPP) 治疗市场的扩大。与此同时,越来越多地使用放射或化疗来治疗癌症以及人们久坐的生活方式将提高市场的增长率。

机会

  • 增加研发活动数量       

此外,市场的增长得益于研发活动的增加。这将为中枢性性早熟 (CPP) 治疗市场的增长提供有利的机会。与此同时,药物审批和上市数量的增加将进一步推动市场的增长率。

此外,对先进技术开发的投资增加和新兴市场数量的增加将为预测期内中枢性性早熟 (CPP) 治疗市场的增长进一步提供有利机会。

限制/挑战

另一方面,治疗相关的高成本将阻碍市场的增长速度。发展中经济体缺乏熟练专业人员和缺乏医疗基础设施将对中枢性性早熟 (CPP) 治疗市场构成挑战。此外,由于 COVID-19 爆发和人们缺乏认识导致临床就诊人数减少,将在 2022-2029 年预测期内起到制约作用并进一步阻碍市场的增长速度。

本中枢性性早熟 (CPP) 治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响,分析了新兴收入来源、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新等方面的机会。如需了解有关中枢性性早熟 (CPP) 治疗市场的更多信息,请联系 Data Bridge Market Research 获取分析师简报,我们的团队将帮助您做出明智的市场决策,实现市场增长。

患者流行病学分析

每 5,000 至 10,000 名女孩中就有 1 名患有中枢性性早熟。尽管这种疾病在男孩中的发病率尚不清楚,但男孩的发病率较低。

中枢性性早熟 (CPP) 治疗市场还为您提供详细的市场分析,包括患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响,以创建更稳健、更队列的多元统计模型,用于预测增长期的市场。

COVID-19 对中枢性性早熟 (CPP) 治疗市场的影响

不同国家爆发的COVID-19疫情和随后的封锁对包括私营医疗保健在内的所有领域的企业都产生了影响。由于某些地方实施了严格的封锁,COVID-19 疫情扰乱了整个医疗保健供应链。COVID-19 疫情对全球不同国家的经济产生了三重影响:直接影响生产和需求、扰乱分销路线以及对企业和金融市场产生财务影响。由于与中枢性性早熟相关的制造企业原材料和药品供应减少,COVID-19 疫情的影响可能会在预测期内阻碍全球中枢性性早熟市场的增长。

全球中枢性性早熟 (CPP) 治疗市场范围

中枢性性早熟 (CPP) 治疗市场根据类型、月份、给药途径、性别、诊断、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

类型

  • 药物

长效 Gnrh 类似物(促性腺激素释放激素)

  • 醋酸亮丙瑞林
  • 曲普瑞林
  • 醋酸组氨瑞林
  • 其他的

辅助治疗

  • 芳香化酶抑制剂
  • 生长激素
  • 非芳香化合成代谢类固醇
  • 外科手术

诊断

  • 血液检查
  • 磁共振成像
  • CT 扫描
  • X 射线

  • 1个月
  • 2 个月
  • 6个月
  • 其他的

给药途径

  • 肠外

皮下

肌肉注射

其他的

性别

  • 女孩们
  • 男孩们

最终用户

  • 医院
  • 专科诊所
  • 家庭护理
  • 其他的

分销渠道

  • 医院药房
  • 零售药店
  • 网上药店
  • 其他的

中枢性性早熟 (CPP) 治疗市场区域分析/见解

对中枢性性早熟 (CPP) 治疗市场进行了分析,并按国家、类型、月份、给药途径、性别、诊断、最终用户和分销渠道提供了市场规模洞察和趋势。

中部性早熟(CPP)治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区(APAC)的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲(MEA)的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在中枢性性早熟 (CPP) 治疗市场占据主导地位,因为该地区拥有完善的医疗基础设施。此外,主要关键参与者对新技术的关注度不断提高,这将进一步推动该地区市场的增长率。

由于亚太地区肥胖率不断上升且医疗保健支出不断增加,预计在 2022 年至 2029 年的预测期内亚太地区将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和中枢性性早熟 (CPP) 治疗市场份额分析

中枢性早熟 (CPP) 治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对中枢性早熟 (CPP) 治疗市场的关注有关。

中枢性性早熟 (CPP) 治疗市场的一些主要参与者包括:

  • 赛诺菲(法国)
  • 辉瑞公司(美国)
  • 葛兰素史克公司 (英国)
  • 诺华公司(瑞士)
  • AbbVie Inc.(美国)
  • F. Hoffmann-La Roche Ltd.(瑞士)
  • Mylan NV(美国)
  • Teva Pharmaceutical Industries Ltd.(爱尔兰)
  • 益普生制药(法国)
  • Arbor Pharmaceuticals(美国)
  • Tolmar Pharmaceuticals, Inc.(美国)
  • GP Pharm(西班牙)
  • Debiopharm(瑞士)
  • 大熊制药有限公司 (韩国)
  • 太阳制药工业有限公司 (印度)
  • 武田药品工业株式会社 (日本)
  • Endo International plc(爱尔兰)
  • 阿斯利康(英国)
  • 强生私人有限公司(美国)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MARKET MONTH COVERAGE GRID

2.8 TYPE OF CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT LIFELINE CURVE

2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.1 DBMR MARKET POSITION GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 EPIDEMIOLOGY

6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: REGULATIONS

7 ASSUMPTIONS

7.1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE

7.2 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH

7.3 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

7.4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER

7.5 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER

7.6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 GROWING PREVALENCE OF HORMONAL DISORDERS

8.1.2 INCREASING PREVALENCE OF OBESITY

8.1.3 INCREASING CASES OF GRANULOSA CELL TUMOURS

8.1.4 INCREASING GLOBAL HEALTHCARE EXPENDITURE

8.1.5 FAVOURABLE GOVERNMENT SUPPORT FOR PRODUCT APPROVAL

8.2 RESTRAINTS

8.2.1 HIGH TREATMENT COSTS

8.2.2 ADVERSE EFFECTS ASSOCIATED WITH DRUG ADMINISTRATION

8.2.3 COMPLICATIONS ASSOCIATED WITH DIAGNOSIS OF CENTRAL PRECOCIOUS PUBERTY

8.3 OPPORTUNITIES

8.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

8.3.2 PRESENCE OF STRONG PRODUCT PIPELINE

8.3.3 LAUNCH OF AWARENESS CAMPAIGNS

8.3.4 AVAILABILITY OF OFF LABEL DRUGS

8.4 CHALLENGES

8.4.1 EXISTENCE OF ALTERNATIVE TREATMENT METHODS

8.4.2 INADEQUATE REIMBURSEMENT POLICIES

8.4.3 PATENT EXPIRY

9 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET

9.1 PRICE IMPACT

9.2 IMPACT ON SUPPLY CHAIN

9.3 IMPACT ON DEMAND

9.4 GOVERNMENT INITIATIVE

9.5 STRATEGIC DECISIONS FOR MANUFACTURERS

9.6 CONCLUSION

10 GLOBAL CENTRAL PRECOCIOUS PUBERTY TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 MEDICATION

10.2.1 LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES)

10.2.1.1 LEUPROLIDE ACETATE

10.2.1.2 TRIPTORELIN

10.2.1.3 HISTRELIN ACETATE

10.2.1.4 OTHERS

10.2.2 ADJUNCTIVE TREATMENTS

10.2.2.1 AROMATASE INHIBITORS

10.2.2.2 GROWTH HORMONE

10.2.2.3 NONAROMATIZABLE ANABOLIC STEROIDS

10.3 SURGERY

11 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH

11.1 OVERVIEW

11.2 1- MONTH

11.3 3- MONTH

11.4 6- MONTH

11.5 OTHERS

12 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 PARENTERAL

12.2.1 SUBCUTANEOUS

12.2.2 INTRAMUSCULAR

12.2.3 OTHERS

12.3 ORAL

12.4 IMPLANTS

12.5 OTHERS

13 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER

13.1 OVERVIEW

13.2 GIRLS

13.3 BOYS

14 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 HOMECARE

14.5 OTHERS

15 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 HOSPITAL PHARMACIES

15.4 RETAIL PHARMACIES

15.5 ONLINE PHARMACIES

15.6 OTHERS

16 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GEOGRAPHY

16.1 OVERVIEW

16.2 NORTH AMERICA

16.2.1 U.S.

16.2.2 CANADA

16.2.3 MEXICO

16.3 EUROPE

16.3.1 GERMANY

16.3.2 FRANCE

16.3.3 U.K

16.3.4 ITALY

16.3.5 NETHERLANDS

16.3.6 SPAIN

16.3.7 RUSSIA

16.3.8 SWITZERLAND

16.3.9 TURKEY

16.3.10 AUSTRIA

16.3.11 NORWAY

16.3.12 HUNGARY

16.3.13 LITHUANIA

16.3.14 IRELAND

16.3.15 POLAND

16.3.16 REST OF EUROPE

16.4 ASIA-PACIFIC

16.4.1 JAPAN

16.4.2 CHINA

16.4.3 AUSTRALIA

16.4.4 SOUTH KOREA

16.4.5 INDIA

16.4.6 SINGAPORE

16.4.7 MALAYSIA

16.4.8 THAILAND

16.4.9 INDONESIA

16.4.10 PHILIPPINES

16.4.11 VIETNAM

16.4.12 REST OF ASIA-PACIFIC

16.5 SOUTH AMERICA

16.5.1 BRAZIL

16.5.2 ARGENTINA

16.5.3 PERU

16.5.4 REST OF SOUTH AMERICA

16.6 MIDDLE EAST & AFRICA

16.6.1 SAUDI ARABIA

16.6.2 SOUTH AFRICA

16.6.3 UAE

16.6.4 ISRAEL

16.6.5 EGYPT

16.6.6 KUWAIT

16.6.7 REST OF MIDDLE EAST & AFRICA

17 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 COMPANY PROFILES

18.1 ABBVIE INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 ENDO INTERNATIONAL PLC

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 DAEWOONG PHARMACEUTICAL CO.,LTD

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPNAY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 IPSEN PHARMA

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENTS

18.6 ARBOR PHARMACEUTICALS

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENT

18.7 ASTRAZENECA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENTS

18.9 SANOFI

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 DEBIOPHARM

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENTS

18.11 GP PHARM

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 MYLAN N.V.

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 PFIZER INC.

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENTS

18.15 TOLMAR PHARMACEUTICALS, INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENT

18.16 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

表格列表

LIST OF TABLES 

TABLE 1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR CENTRAL PRECOCIOUS PUBERTY

TABLE 3 MEDICINES SUBJECTED TO PATENT EXPIRY

TABLE 4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE, 2019-2027 (EURO MILLION)

TABLE 5 GLOBAL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 6 GLOBAL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 7 GLOBAL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 8 GLOBAL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 9 GLOBAL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 10 GLOBAL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 11 GLOBAL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 12 GLOBAL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 13 GLOBAL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 14 GLOBAL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 15 GLOBAL SURGERIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 16 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH, 2019-2027 (EURO MILLION)

TABLE 17 GLOBAL 1- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 18 GLOBAL 3- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 19 GLOBAL 6- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 20 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 21 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)

TABLE 22 GLOBAL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 23 GLOBAL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 24 GLOBAL ORAL IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 25 GLOBAL IMPLANT IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 26 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 27 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER, 2019-2027 (EURO MILLION)

TABLE 28 GLOBAL GIRLS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 29 GLOBAL BOYS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 30 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER, 2019-2027 (EURO MILLION)

TABLE 31 GLOBAL HOSPITALS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 32 GLOBAL SPECILATY CLINICS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 33 GLOBAL HOME CARE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 34 GLOBAL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 35 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)

TABLE 36 GLOBAL DIRECT TENDER IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 37 GLOBAL HOSPITAL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 38 GLOBAL RETAIL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 39 GLOBAL ONLINE PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 40 GLOBAL OTHERS IN CNETRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)

TABLE 41 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)

TABLE 42 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 43 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 44 NORTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 45 NORTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 46 NORTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 47 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 48 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 49 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 50 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 51 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 52 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 53 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 54 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 55 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 56 NORTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 57 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 58 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 59 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 60 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 61 U.S. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 62 U.S. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 63 U.S. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 64 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 65 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 66 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 67 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 68 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 69 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 70 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 71 U.S. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 72 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 73 U.S. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 74 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 75 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 76 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 77 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 78 CANADA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 79 CANADA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 80 CANADA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 81 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 82 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 83 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 84 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 85 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 86 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 87 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 88 CANADA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 89 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 90 CANADA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 91 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 92 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 93 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 94 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 95 MEXICO MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 96 MEXICO LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 97 MEXICO ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 98 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 99 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 100 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 101 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 102 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 103 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 104 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 105 MEXICO OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 106 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 107 MEXICO PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 108 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 109 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 110 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 111 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 112 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 113 EUROPE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 114 EUROPE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 115 EUROPE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 116 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 117 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 118 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 119 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 120 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 121 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 122 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 123 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 124 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 125 EUROPE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 126 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 127 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 128 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 129 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 130 GERMANY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 131 GERMANY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 132 GERMANY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 133 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 134 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 135 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 136 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 137 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 138 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 139 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 140 GERMANY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 141 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 142 GERMANY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 143 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 144 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 145 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 146 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 147 FRANCE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 148 FRANCE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 149 FRANCE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 150 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 151 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 152 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 153 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 154 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 155 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 156 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 157 FRANCE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 158 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 159 FRANCE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 160 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 161 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 162 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 163 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 164 U.K. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 165 U.K. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 166 U.K. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 167 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 168 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 169 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 170 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 171 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 172 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 173 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 174 U.K. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 175 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 176 U.K. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 177 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 178 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 179 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 180 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 181 ITALY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 182 ITALY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 183 ITALY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 184 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 185 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 186 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 187 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 188 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 189 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 190 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 191 ITALY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 192 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 193 ITALY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 194 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 195 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 196 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 197 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 198 NETHERLANDS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 199 NETHERLANDS LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 200 NETHERLANDS ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 201 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 202 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 203 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 204 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 205 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 206 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 207 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 208 NETHERLANDS OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 209 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 210 NETHERLANDS PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 211 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 212 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 213 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 214 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 215 SPAIN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 216 SPAIN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 217 SPAIN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 218 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 219 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 220 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 221 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 222 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 223 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 224 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 225 SPAIN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 226 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 227 SPAIN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 228 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 229 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 230 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 231 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 232 RUSSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 233 RUSSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 234 RUSSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 235 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 236 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 237 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 238 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 239 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 240 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 241 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 242 RUSSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 243 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 244 RUSSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 245 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 246 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 247 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 248 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 249 SWITZERLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 250 SWITZERLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 251 SWITZERLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 252 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 253 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 254 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 255 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 256 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 257 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 258 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 259 SWITZERLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 260 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 261 SWITZERLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 262 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 263 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 264 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 265 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 266 TURKEY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 267 TURKEY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 268 TURKEY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 269 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 270 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 271 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 272 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 273 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 274 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 275 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 276 TURKEY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 277 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 278 TURKEY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 279 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 280 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 281 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 282 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 283 AUSTRIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 284 AUSTRIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 285 AUSTRIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 286 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 287 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 288 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 289 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 290 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 291 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 292 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 293 AUSTRIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 294 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 295 AUSTRIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 296 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 297 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 298 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 299 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 300 NORWAY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 301 NORWAY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 302 NORWAY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 303 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 304 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 305 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 306 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 307 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 308 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 309 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 310 NORWAY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 311 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 312 NORWAY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 313 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 314 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 315 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 316 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 317 HUNGARY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 318 HUNGARY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 319 HUNGARY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 320 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 321 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 322 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 323 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 324 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 325 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 326 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 327 HUNGARY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 328 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 329 HUNGARY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 330 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 331 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 332 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 333 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 334 LITHUANIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 335 LITHUANIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 336 LITHUANIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 337 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 338 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 339 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 340 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 341 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 342 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 343 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 344 LITHUANIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 345 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 346 LITHUANIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 347 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 348 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 349 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 350 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 351 IRELAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 352 IRELAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 353 IRELAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 354 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 355 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 356 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 357 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 358 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 359 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 360 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 361 IRELAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 362 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 363 IRELAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 364 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 365 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 366 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 367 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 368 POLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 369 POLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 370 POLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 371 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 372 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 373 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 374 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 375 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 376 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 377 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 378 POLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 379 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 380 POLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 381 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 382 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 383 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 384 REST OF EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 385 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 386 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 387 ASIA-PACIFIC MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 388 ASIA-PACIFIC LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 389 ASIA-PACIFIC ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 390 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 391 ASIA-PACIFIC LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 392 ASIA-PACIFIC LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 393 ASIA-PACIFIC HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 394 ASIA-PACIFIC HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 395 ASIA-PACIFIC TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 396 ASIA-PACIFIC TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 397 ASIA-PACIFIC OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 398 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 399 ASIA-PACIFIC PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 400 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 401 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 402 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 403 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 404 JAPAN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 405 JAPAN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 406 JAPAN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 407 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 408 JAPAN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 409 JAPAN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 410 JAPAN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 411 JAPAN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 412 JAPAN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 413 JAPAN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 414 JAPAN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 415 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 416 JAPAN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 417 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 418 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 419 JAPAN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 420 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 421 CHINA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 422 CHINA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 423 CHINA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 424 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 425 CHINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 426 CHINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 427 CHINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 428 CHINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 429 CHINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 430 CHINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 431 CHINA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 432 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 433 CHINA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 434 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 435 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 436 CHINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 437 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 438 AUSTRALIA. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 439 AUSTRALIA. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 440 AUSTRALIA. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 441 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 442 AUSTRALIA. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 443 AUSTRALIA. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 444 AUSTRALIA. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 445 AUSTRALIA. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 446 AUSTRALIA. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 447 AUSTRALIA. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 448 AUSTRALIA. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 449 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 450 AUSTRALIA. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 451 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 452 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 453 AUSTRALIA. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 454 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 455 SOUTH KOREA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 456 SOUTH KOREA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 457 SOUTH KOREA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 458 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 459 SOUTH KOREA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 460 SOUTH KOREA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 461 SOUTH KOREA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 462 SOUTH KOREA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 463 SOUTH KOREA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 464 SOUTH KOREA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 465 SOUTH KOREA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 466 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 467 SOUTH KOREA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 468 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 469 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 470 SOUTH KOREA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 471 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 472 INDIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 473 INDIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 474 INDIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 475 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 476 INDIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 477 INDIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 478 INDIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 479 INDIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 480 INDIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 481 INDIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 482 INDIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 483 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 484 INDIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 485 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 486 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 487 INDIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 488 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 489 SINGAPORE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 490 SINGAPORE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 491 SINGAPORE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 492 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 493 SINGAPORE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 494 SINGAPORE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 495 SINGAPORE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 496 SINGAPORE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 497 SINGAPORE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 498 SINGAPORE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 499 SINGAPORE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 500 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 501 SINGAPORE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 502 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 503 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 504 SINGAPORE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 505 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 506 MALAYSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 507 MALAYSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 508 MALAYSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 509 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 510 MALAYSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 511 MALAYSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 512 MALAYSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 513 MALAYSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 514 MALAYSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 515 MALAYSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 516 MALAYSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 517 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 518 MALAYSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 519 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 520 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 521 MALAYSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 522 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 523 THAILAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 524 THAILAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 525 THAILAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 526 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 527 THAILAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 528 THAILAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 529 THAILAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 530 THAILAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 531 THAILAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 532 THAILAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 533 THAILAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 534 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 535 THAILAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 536 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 537 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 538 THAILAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 539 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 540 INDONESIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 541 INDONESIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 542 INDONESIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 543 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 544 INDONESIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 545 INDONESIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 546 INDONESIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 547 INDONESIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 548 INDONESIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 549 INDONESIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 550 INDONESIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 551 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 552 INDONESIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 553 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 554 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 555 INDONESIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 556 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 557 PHILIPPINES MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 558 PHILIPPINES LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 559 PHILIPPINES ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 560 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 561 PHILIPPINES LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 562 PHILIPPINES LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 563 PHILIPPINES HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 564 PHILIPPINES HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 565 PHILIPPINES TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 566 PHILIPPINES TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 567 PHILIPPINES OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 568 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 569 PHILIPPINES PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 570 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 571 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 572 PHILIPPINES CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 573 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 574 VIETNAM MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 575 VIETNAM LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 576 VIETNAM ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 577 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 578 VIETNAM LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 579 VIETNAM LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 580 VIETNAM HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 581 VIETNAM HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 582 VIETNAM TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 583 VIETNAM TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 584 VIETNAM OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 585 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 586 VIETNAM PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 587 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 588 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 589 VIETNAM CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 590 REST OF ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 591 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 592 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 593 SOUTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 594 SOUTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 595 SOUTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 596 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 597 SOUTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 598 SOUTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 599 SOUTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 600 SOUTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 601 SOUTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 602 SOUTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 603 SOUTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 604 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 605 SOUTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 606 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 607 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 608 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 609 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 610 BRAZIL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 611 BRAZIL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 612 BRAZIL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 613 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 614 BRAZIL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 615 BRAZIL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 616 BRAZIL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 617 BRAZIL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 618 BRAZIL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 619 BRAZIL TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 620 BRAZIL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 621 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 622 BRAZIL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 623 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 624 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 625 BRAZIL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 626 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 627 ARGENTINA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 628 ARGENTINA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 629 ARGENTINA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 630 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 631 ARGENTINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 632 ARGENTINA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 633 ARGENTINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 634 ARGENTINA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 635 ARGENTINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 636 ARGENTINA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 637 ARGENTINA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 638 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 639 ARGENTINA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 640 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 641 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 642 ARGENTINA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 643 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 644 PERU. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 645 PERU. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 646 PERU. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 647 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 648 PERU. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 649 PERU. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 650 PERU. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 651 PERU. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 652 PERU. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 653 PERU. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 654 PERU. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 655 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 656 PERU. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 657 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 658 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 659 PERU. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 660 REST OF SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 661 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 662 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 663 MIDDLE EAST & AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 664 MIDDLE EAST & AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 665 MIDDLE EAST & AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 666 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 667 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 668 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 669 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 670 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 671 MIDDLE EAST & AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 672 MIDDLE EAST & AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 673 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 674 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 675 MIDDLE EAST & AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 676 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 677 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 678 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 679 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 680 SAUDI ARABIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 681 SAUDI ARABIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 682 SAUDI ARABIAADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 683 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 684 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 685 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 686 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 687 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 688 SAUDI ARABIATRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 689 SAUDI ARABIATRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 690 SAUDI ARABIAOTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 691 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 692 SAUDI ARABIAPARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 693 SAUDI ARABIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 694 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 695 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 696 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 697 SOUTH AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 698 SOUTH AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 699 SOUTH AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 700 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 701 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 702 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 703 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 704 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 705 SOUTH AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 706 SOUTH AFRICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 707 SOUTH AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 708 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 709 SOUTH AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 710 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 711 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 712 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 713 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 714 UAE. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 715 UAE. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 716 UAE. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 717 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 718 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 719 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 720 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 721 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 722 UAE. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 723 UAE. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 724 UAE. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 725 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 726 UAE. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 727 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 728 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 729 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 730 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 731 ISRAEL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 732 ISRAEL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 733 ISRAEL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 734 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 735 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 736 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 737 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 738 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 739 ISRAELTRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 740 ISRAELTRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 741 ISRAEL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 742 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 743 ISRAEL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 744 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 745 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 746 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 747 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 748 EGYPT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 749 EGYPT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 750 EGYPT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 751 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 752 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 753 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 754 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 755 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 756 EGYPT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 757 EGYPT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 758 EGYPT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 759 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 760 EGYPT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 761 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 762 EGYPTCENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 763 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 764 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 765 KUWAIT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 766 KUWAIT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 767 KUWAIT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 768 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 769 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 770 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 771 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 772 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 773 KUWAIT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 774 KUWAIT TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 775 KUWAIT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 776 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 777 KUWAIT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 778 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 779 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 780 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 781 REST OF MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

图片列表

LIST OF FIGURES 

FIGURE 1 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: MARKET MONTH COVERAGE GRID

FIGURE 8 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 10 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 13 GROWING PREVALENCE OF HORMONAL DISORDERS AND FAVORABLE GOVERNMENT SUPPORT FOR PRODUCT APPROVAL ARE DRIVING THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 14 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN 2020 & 2027

FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING REGION IN GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET

FIGURE 17 PER CAPITA HEALTHCARE EXPENDITURE, IN 2018 (USD)

FIGURE 18 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, 2019

FIGURE 19 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, 2019-2027 (EURO MILLION)

FIGURE 20 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 21 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, 2019

FIGURE 23 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, 2019-2027 (EURO MILLION)

FIGURE 24 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, CAGR (2020-2027)

FIGURE 25 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY MONTH, LIFELINE CURVE

FIGURE 26 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 27 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)

FIGURE 28 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 29 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, 2019

FIGURE 31 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, 2019-2027 (EURO MILLION)

FIGURE 32 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, CAGR (2020-2027)

FIGURE 33 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 34 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, 2019

FIGURE 35 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, 2019-2027 (EURO MILLION)

FIGURE 36 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, CAGR (2020-2027)

FIGURE 37 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 39 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)

FIGURE 40 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 41 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 43 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2019)

FIGURE 44 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2020 & 2027)

FIGURE 45 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY REGION (2019 & 2027)

FIGURE 46 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 47 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 48 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 49 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 50 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 51 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 52 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 53 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 54 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 55 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 56 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 57 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 58 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 59 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 60 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 61 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 62 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 63 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 64 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 65 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 66 SOUTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 67 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 68 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 69 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 70 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 71 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 72 GLOBAL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)

FIGURE 73 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)

FIGURE 74 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)

FIGURE 75 ASIA-PACIFIC CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET: COMPANY SHARE 2019 (%)

 

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market value for Central Precocious Puberty (CPP) Treatment Market is expected USD 2,663.78 million by 2029.
The Central Precocious Puberty (CPP) Treatment Market is to grow at a CAGR of 7.60% during the forecast by 2029
The expansion of the Global Central Precocious Puberty (CPP) Treatment Market will be fueled by the sedentary lifestyle of people and rising prevalence of hormonal disorders. Additionally, increasing expenditure on healthcare infrastructure and growing incidences of obesity will enhance the growth rate of global central precocious puberty (CPP) treatment market.
The major players operating in the Central Precocious Puberty (CPP) Treatment Market are Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Ipsen Pharma (France), Arbor Pharmaceuticals (US), Tolmar Pharmaceuticals, Inc. (US), GP Pharm (Spain), Debiopharm (Switzerland), DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Endo International plc (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US).